CTKB Q2 2021 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CTKBCytek Biosciences, Inc.

$553M

Q2 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$30M+58.9% YoY

Gross Profit

$20M64.9% margin

Operating Income

$4M12.5% margin

Net Income

$3M8.8% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+25.3%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$230M

Total Liabilities

$241M

Stockholders' Equity

-$11M

Cash & Equivalents

$160M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$19M	+58.9%
Gross Profit	$20M	$8M	+138.8%
Operating Income	$4M	-$218,000	+1848.2%
Net Income	$3M	$8M	-67.1%

Revenue Segments

Product

$29M70%

Service

$12M30%

Geographic Segments

UNITED STATES

$17M57%

E M E A

$10M32%

Asia Pacific

$3M11%

Other

$111,0000%